Dr. August Troendle

CEO of Medpace - Leadership Excellence in Clinical Research

Profile

Dr. Troendle has been the Chief Executive Officer and Chairman of the Board of Directors of Medpace since he founded the company in July 1992. Before founding Medpace, Dr. Troendle served as a manager from 1987 to 1992 at Sandoz (Novartis), where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987, Dr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA.

Dr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018, as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008, as a director of LIB Therapeutics, LLC since 2015, as a director of CinCor Pharma, Inc. from March 2018 to November 2021, and as a director of CinRx Pharma, LLC since 2015. Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine and his Master of Business Administration from Boston University.

FIRM PROFILE

Dr. August Troendle, a noted medical doctor and scientist in the study of lipid-altering agents, saw an opportunity in 1992 to offer a more innovative way to conduct clinical trials on behalf of biopharmaceutical sponsors. His vision for a high-science, full-service CRO with expertise in specific therapeutic areas led to the founding of Medpace. The company capitalized on an unmet need in the life science sector with a model that delivers a much higher level of outsourcing that combines the expertise of noted industry medical doctors with regulatory and operational professionals who provide therapeutic and regulatory expertise for the most difficult clinical studies.

Since then, Medpace has grown to over 5,800 associates across 41 countries. Growing organically enables us to stay focused on our mission AND our values; to create a unique culture where employees all contribute to a greater purpose: to make a difference in the lives of millions today, tomorrow, and for years to come. Together, we improve lives.

Medpace’s primary client is a small to mid-size biopharma company who is looking to partner under a full-service model where our medical, regulatory, and operational expertise can help accelerate development. We understand the complex challenges facing biotechs. Our culture and our operating structure are purposely designed to accommodate efficient partnering, important for emerging biotechs with limited resources and sometimes limited experience.
Driven by a full-service CRO model that coordinates and integrates all services for our clients, Medpace provides an accountable, seamless, integrated, and efficient platform for executing clinical research – increasing quality and speed while significantly reducing the need for duplicate management oversight. More than a “set of extra hands”, we are an extension of your team – embedding medical, regulatory, and operational expertise into your trials to navigate and overcome challenges. It’s how we make the complex seamless. And it’s why we are Trusted by Biotech.

Our unique global partnering philosophy emphasizes an uncompromising commitment to clinical research and to the highest level of ethical standards and performance in our jobs. We are selective about the projects we engage in because we are devoted to quality and providing our partners with best-in-class service.

Our Mission

Accelerating the global development of safe and effective medical therapeutics.

Medpace’s dedicated teams serve as an extension of your team – we engage quickly and provide strategic thinking – ensuring start-up times are met, superior quality, and the most efficient delivery of every phase of your clinical trial. Our therapeutic and regulatory experts are committed to streamlining your path to approval so every partnership is designed to create research solutions focused on your critical needs.